FIELD: medicine.
SUBSTANCE: invention relates to composition for treating malignant disease, which contains ecteinascidin of general formula 
and disaccharide.
EFFECT: invention allows to provide compositions, which have high stability in storage, and essentially reduce formation of admixtures during liophylisation process and storage of ecteinascidin compositions.
36 cl, 5 ex, 19 tbl, 9 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| PREPARATIONS | 2006 |
|
RU2429845C2 |
| INJECTION PHARMACEUTICAL COMPOSITION COMPRISING TRABECTEDIN FOR USE OUTSIDE THE GASTROINTESTINAL TRACT AND A METHOD FOR PREPARING IT | 2017 |
|
RU2738741C2 |
| IMMUNOGLOBULIN COMPOSITIONS AND PRODUCTION PROCEDURE | 2004 |
|
RU2358763C2 |
| STABLE PHARMACEUTICAL PREPARATION BASED ON THE PD-1 ANTIBODY AND ITS USE IN MEDICINE | 2016 |
|
RU2731418C2 |
| STABLE COMPOSITIONS OF IMMUNOGLOBULIN SINGLE VARIABLE DOMAIN AND THEIR USE | 2014 |
|
RU2773172C2 |
| LYOPHILISED COMPOSITIONS CCI-779 | 2004 |
|
RU2345772C2 |
| PRODUCTION OF ANTIBODY-DRUG CONJUGATE AND ITS LYOPHILIZATION | 2018 |
|
RU2789476C2 |
| PROTEIN STABILISATION FORMULATION FREE FROM MAMMALIAN EXCIPIENTS | 2010 |
|
RU2539388C2 |
| PHARMACEUTICAL COMPOSITIONS OF SAPOSIN C AND METHODS FOR TREATING CANCER | 2018 |
|
RU2767199C1 |
| STABLE COMPOSITIONS OF ANTIBODIES AGAINST PROGRAMMABLE DEATH RECEPTOR OF PD-1 PERSON AND RELATED TREATMENT | 2012 |
|
RU2633509C2 |
